<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04374877</url>
  </required_header>
  <id_info>
    <org_study_id>SRF388-101</org_study_id>
    <secondary_id>KNC16</secondary_id>
    <nct_id>NCT04374877</nct_id>
  </id_info>
  <brief_title>Study of SRF388 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1/1b Study of SRF388 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Surface Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Surface Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of&#xD;
      SRF388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in&#xD;
      patients with solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/1b, open-label, first-in-human (FIH), dose-escalation and expansion study&#xD;
      of SRF388, a monoclonal antibody targeting IL-27, as a monotherapy and in combination in&#xD;
      patients with solid tumors that will be conducted in 3 parts:&#xD;
&#xD;
        -  Part A: SRF388 monotherapy dose-escalation portion of the study will evaluate the&#xD;
           safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of SRF388 as&#xD;
           monotherapy in patients with advanced solid tumors.&#xD;
&#xD;
        -  Part B: SRF388 monotherapy expansion cohorts will evaluate the safety, efficacy,&#xD;
           tolerability, PK, and pharmacodynamics of SRF388 monotherapy in patients with advanced&#xD;
           or metastatic ccRCC (any clear cell component in the histologic definition) and advanced&#xD;
           or metastatic HCC in indication specific cohorts.&#xD;
&#xD;
        -  Part C will evaluate the safety, preliminary efficacy, tolerability, and PK of SRF388 in&#xD;
           combination with pembrolizumab in patients with advanced RCC or HCC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>[Part A] Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Assessed during first 28 days of treatment</time_frame>
    <description>Evaluation of DLT of SRF388 as a monotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[Part B] Confirmed objective response rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>ORR will be estimated by the percentage of patients achieving a best overall response of CR or PR per RECIST v1.1 and iRECIST.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[Part C] DLT</measure>
    <time_frame>Assessed during first 21 days of treatment</time_frame>
    <description>Evaluation of DLT of SRF388 in combination with pembrolizumab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[Part C] Summary of adverse events (AEs) based on treatment emergent AEs (TEAEs)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Safety and tolerability of SRF388 + pembrolizumab will be assessed by summarizing AEs and will be based on TEAEs. A TEAE is an AE that emerges or worsens in the period from the first dose of study treatment to 30 days after the last dose of study drug assessed by per CTCAE version 5.0 or higher.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>[Part A, Part B] Safety Analysis: Summary of adverse events (AEs) and based on treatment-emergent AEs (TEAEs)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Safety and tolerability of SRF388 will be assessed by summarizing adverse events (AEs) and will be based on treatment-emergent AEs (TEAEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part A, Part B, Part C] Pharmacokinetics (PK) of SRF388</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Serum concentrations of SRF388 will be collected and analyzed to evaluate the PK of SRF388.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part A, Part B] Pharmacodynamics of SRF388 (pSTAT levels)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Pharmacodynamics of SRF388 will be evaluated in immune cell subsets via whole blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part A, Part C] Objective response rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>ORR will be estimated by the percentage of patients achieving a best overall response of CR or PR per RECIST v1.1 and iRECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part A, Part B, Part C] Duration of response (DoR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>DoR is defined as the time from the first documented response (CR or PR) to documented disease progression as determined by applicable disease criteria, or documented death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part A, Part B, Part C] Disease control rate (DCR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>DCR is defined as the percentage of patients with CR, partial PR, or stable disease lasting a minimum of 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part A, Part B, Part C] Progression-free survival (PFS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>PFS is defined as the time from the first treatment on study with study drug to documented disease progression as determined by applicable disease criteria or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part C] Serum concentration of EBI3</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Serum will be collected to assess EBI3 correlation with outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part C] Anti-drug Antibodies (ADAs) to SRF388</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Serum will be collected and assessed for the development of ADAs to SRF388.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Part A Monotherapy Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Part A monotherapy dose escalation portion of the study will evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of SRF388 as monotherapy in up to 42 patients with advanced solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Indication-specific SRF388 Monotherapy Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B monotherapy expansion will evaluate the safety, tolerability, PK, pharmacodynamics, and efficacy of SRF388 monotherapy at the recommended phase 2 dose (RP2D) in up to 40 patients with ccRCC (any clear cell component in the histologic definition) and up to 40 patients with HCC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C SRF388 in Combination with Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part C will evaluate the safety, preliminary efficacy, tolerability, and PK of SRF388 in combination with pembrolizumab in patients with advanced RCC or HCC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRF388</intervention_name>
    <description>SRF388 is a fully human IgG1 antibody against IL-27. Inhibition of IL-27 with SRF388 reduces STAT1 phosphorylation leading to increased pro-inflammatory (anti-tumor) cytokine secretion (e.g., IFN-g, TNF-a) and decreased expression of inhibitory immune checkpoint receptors (e.g., PD-L1, TIGIT, LAG3) on immune cells that may result in anticancer therapeutic activity.</description>
    <arm_group_label>Part A Monotherapy Expansion</arm_group_label>
    <arm_group_label>Part B Indication-specific SRF388 Monotherapy Expansion</arm_group_label>
    <arm_group_label>Part C SRF388 in Combination with Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab by intravenous (IV) infusion</description>
    <arm_group_label>Part C SRF388 in Combination with Pembrolizumab</arm_group_label>
    <other_name>Keytruda®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part A and Part B Abbreviated Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years of age&#xD;
&#xD;
          -  Locally advanced or metastatic (Stage IV) solid tumor that has progressed during or&#xD;
             after standard therapy, and for whom no available therapies are appropriate (based on&#xD;
             investigator judgment)&#xD;
&#xD;
          -  Patients in Part B with advance or metastatic ccRCC or HCC must have at least 1&#xD;
             measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1&#xD;
&#xD;
          -  Patients with HCC in Part B must have at least 1 measurable target lesion according to&#xD;
             modified RECIST (mRECIST)&#xD;
&#xD;
          -  Patients with HCC must have unresectable disease, Barcelona Clinic Liver Cancer&#xD;
             (BCLC1) Stage B (not eligible for transcatheter arterial chemoembolization [TACE]) or&#xD;
             Stage C&#xD;
&#xD;
          -  For patients in Part B with ccRCC, demonstrated progressive disease (PD) during or&#xD;
             after the most recent treatment regimen. Prior treatment history must include&#xD;
             progression during or after treatment with regimen(s) that have included a vascular&#xD;
             endothelial growth growth factor (VEGF)-targeted agent and an immune checkpoint&#xD;
             inhibitor. Patients who did not progress on but discontinued the VEGF-targeted agent&#xD;
             for toxicity or intolerability are permitted.&#xD;
&#xD;
          -  For patients in Part B with HCC, demonstrated PD during or after the most recent&#xD;
             treatment regimen. Prior treatment history must include progression during or after&#xD;
             treatment with a VEGF-targeted agent. Patients who did not progress on but&#xD;
             discontinued the VEGF-targeted agent for toxicity or intolerability are permitted.&#xD;
&#xD;
          -  For Part B patients in the tumor biopsy subsets only, must have tumor tissue that is&#xD;
             accessible for pretreatment and on-treatment tumor biopsy in the opinion of the&#xD;
             Investigator and be willing to undergo pretreatment and on-treatment biopsies per&#xD;
             protocol&#xD;
&#xD;
          -  Serum creatinine clearance ≥ 30 mL/min per Cockcroft-Gault formula or serum creatinine&#xD;
             ≤ 2.0 x the upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN if elevated because of Gilbert's syndrome and ≤&#xD;
             2 x ULN for patients with HCC or patients with known liver metastases)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) &lt; 2.5 x&#xD;
             ULN (&lt; 5 x ULN if liver metastasis or for patients with HCC)&#xD;
&#xD;
          -  For patients with HCC, Child-Pugh class A or B7 with a serum albumin ≥ 2.8 g/dL (≥ 28&#xD;
             g/L)&#xD;
&#xD;
          -  Adequate hematologic function, defined as absolute neutrophil count (ANC) ≥ 1.0 x&#xD;
             109/L, hemoglobin ≥ 9.0 g/dL, and platelet count ≥ 100 x 109/L. For patients with HCC,&#xD;
             platelet count ≥ 75 x 109/L without transfusion&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
        Part C Abbreviated Inclusion Criteria:&#xD;
&#xD;
          -  Advanced RCC of any histology or advanced HCC previously treated with at least one&#xD;
             systemic anticancer therapy&#xD;
&#xD;
          -  Patients with HCC must have unresectable disease, Barcelona Clinic Liver Cancer (BCLC)&#xD;
             Stage B (not eligible for transcatheter arterial chemoembolization) or Stage C&#xD;
&#xD;
          -  At least 1 measurable lesion per RECIST 1.1&#xD;
&#xD;
          -  Patients with HCC must have at least 1 measurable target lesion according to modified&#xD;
             RECIST (mRECIST)&#xD;
&#xD;
          -  ANC ≥1000/µL (1.0 x 109/L)&#xD;
&#xD;
          -  Platelets ≥100 000/µL (≥ 100 x 109/L)&#xD;
&#xD;
          -  Hemoglobin for participants with RCC: ≥9.0 g/dL1; for participants with HCC: ≥8.5&#xD;
             g/dL1&#xD;
&#xD;
          -  Creatinine OR measured or calculated creatinine clearance (GFR can also be used in&#xD;
             place of creatinine or CrCl) ≤1.5 × ULN OR ≥30 mL/min for participant with creatinine&#xD;
             levels &gt;1.5 × institutional ULN&#xD;
&#xD;
          -  Total bilirubin ≤1.5 × ULN OR direct bilirubin ≤ULN for participants with total&#xD;
             bilirubin levels &gt;1.5 × ULN&#xD;
&#xD;
          -  AST (SGOT) and ALT (SGPT) ≤2.5 × ULN (≤5 × ULN for participants with liver metastases)&#xD;
&#xD;
          -  International normalized ratio (INR) OR prothrombin time (PT) Activated partial&#xD;
             thromboplastin time (aPTT) ≤1.5 × ULN unless participant is receiving anticoagulant&#xD;
             therapy as long as PT or aPTT is within therapeutic range of intended use of&#xD;
             anticoagulants&#xD;
&#xD;
          -  For patients with HCC, Child-Pugh class A or B7 with a serum albumin ≥ 2.8 g/dL (≥ 28&#xD;
             g/L)&#xD;
&#xD;
          -  Willingness of male and female patients who are not surgically sterile or&#xD;
             postmenopausal to use medically acceptable methods of birth control for the duration&#xD;
             of the study drug period (or beginning 14 days before the initiation of pembrolizumab&#xD;
             for oral contraception), including 75 days after the last dose of SRF388 or 120 days&#xD;
             after the last dose of pembrolizumab; male patients must refrain from donating sperm&#xD;
             during this period. Sexually active men, and women using oral contraceptive pills,&#xD;
             should also use barrier contraception with spermicide. Azoospermic male patients and&#xD;
             WCBP who are continuously not heterosexually active are exempt from contraceptive&#xD;
             requirements. However, female patients must still undergo pregnancy testing as&#xD;
             described in this section.&#xD;
&#xD;
        Part C Abbreviated Inclusion Criteria Specific to Patients with RCC or HCC from Part A or&#xD;
        Part B:&#xD;
&#xD;
          -  Progressed on SRF388 by RECIST 1.1&#xD;
&#xD;
          -  Did not experience prior Grade ≥ 3 toxicity related to SRF388&#xD;
&#xD;
          -  Willingness to undergo pretreatment core or excisional biopsy if deemed safe and tumor&#xD;
             is accessible, in the opinion of the Investigator&#xD;
&#xD;
          -  Has received no systemic anticancer therapies between SRF388 doses&#xD;
&#xD;
        Part A and Part B Abbreviated Exclusion Criteria:&#xD;
&#xD;
          -  Previously received an anti-IL-27 antibody or anti-IL-27 targeted therapy&#xD;
&#xD;
          -  For patients in Part B with renal cell carcinoma (RCC), non-clear cell RCC histology&#xD;
&#xD;
          -  For patients with HCC, fibrolamellar or mixed hepatocellular cholangiocarcinoma&#xD;
&#xD;
          -  History of Grade 4 allergic or anaphylactic reaction to any monoclonal antibody&#xD;
             therapy or any excipient in the study drugs&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to Screening&#xD;
&#xD;
          -  Unstable or severe uncontrolled medical condition (eg, unstable cardiac function,&#xD;
             unstable pulmonary condition including pneumonitis and/or interstitial lung disease,&#xD;
             uncontrolled diabetes) or any important medical illness or abnormal laboratory finding&#xD;
             that would, in the Investigator's judgment, increase the risk to the patient&#xD;
             associated with his or her participation in the study&#xD;
&#xD;
        Part C Abbreviated Exclusion Criteria:&#xD;
&#xD;
          -  Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks prior to the first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Previously received an anti-IL 27 antibody or anti-IL 27 targeted therapy (exception&#xD;
             to patients who received SRF388 in Part A or Part B)&#xD;
&#xD;
          -  No prior systemic therapy for unresectable or metastatic disease&#xD;
&#xD;
          -  Received &gt; 5 prior systemic regimens for unresectible or metastatic disease (prior&#xD;
             PD-(L)1 inhibitors are allowed if the patient did not discontinue therapy due to ≥&#xD;
             Grade 3 drug-related toxicity)&#xD;
&#xD;
          -  For patients with HCC, fibrolamellar histology or mixed hepatocellular&#xD;
             cholangiocarcinoma&#xD;
&#xD;
          -  For patients with HCC, moderate or severe ascites&#xD;
&#xD;
          -  For patients with HCC, inability to undergo disease evaluation with triphasic computed&#xD;
             tomography or magnetic resonance imaging because of contrast allergy or other&#xD;
             contraindication&#xD;
&#xD;
          -  For patients with HCC, imaging findings consistent with ≥ 50% liver occupation by HCC&#xD;
             tumors&#xD;
&#xD;
          -  History of Grade 4 allergic or anaphylactic reaction to any monoclonal antibody&#xD;
             therapy or any excipient in the study drugs&#xD;
&#xD;
          -  Surgeries that required general anesthesia must be completed at least 2 weeks before&#xD;
             first study drug administration&#xD;
&#xD;
          -  Prior autologous stem cell transplant ≤ 3 months before the first dose&#xD;
&#xD;
          -  Prior allogeneic hematopoietic cell transplant within 6 months of the first dose or&#xD;
             with a history of or current clinical Graft-Versus-Host Disease&#xD;
&#xD;
          -  Has had an allogenic tissue/solid organ transplant&#xD;
&#xD;
          -  Other unstable or severe uncontrolled medical condition (eg, unstable cardiac&#xD;
             function, unstable pulmonary condition, uncontrolled diabetes) or any important&#xD;
             medical illness or abnormal laboratory finding that would, in the Investigator's&#xD;
             judgment, increase the risk to the patient associated with his or her participation in&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren Harshman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Surface Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Bowers</last_name>
    <phone>1-978-954-7207</phone>
    <email>bbowers@surfaceoncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daneng Li</last_name>
      <phone>626-471-9200</phone>
    </contact>
    <investigator>
      <last_name>Daneng Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California (USC) - Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiomara Menendez, RN</last_name>
      <phone>323-409-4368</phone>
      <email>menendez_x@med.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Harton, MS</last_name>
      <phone>(323) 865-0454</phone>
      <email>Lisa.Harton@med.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony El-Khoueiry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ria Conti</last_name>
      <phone>415-514-2259</phone>
      <email>Maria.Conti@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Kate Kelley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Leonard M. Miller School of Medicine (UMMSM)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josefina Sanchez</last_name>
      <phone>305-243-5491</phone>
      <email>Jxs2844@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Lynn Feun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karly Griffin</last_name>
      <phone>617-632-6287</phone>
      <email>Karly_Griffin@DFCI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Charlene Mantia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System (UMHS)</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Breanna Bladowski</last_name>
      <phone>734-936-7813</phone>
      <email>bbladows@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Ulka Vaishampayan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine - St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katlyn Kraft</last_name>
      <phone>314-747-5440</phone>
      <email>katlyn.kraft@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Archambault</last_name>
      <phone>314-362-8246</phone>
      <email>archambaultj@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Morgensztern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rushka Kallicharan Smith</last_name>
      <email>Rushka.Kallicharan-Smith@RoswellPark.org</email>
    </contact>
    <investigator>
      <last_name>Saby George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Hammad</last_name>
      <phone>917-510-7790</phone>
      <email>Ashley.hammad@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Marron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>taussigresearch@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Moshe Ornstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center (OUHSC) - Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>405-271-8778</phone>
      <email>Phase1-Referrals@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Abhishek Tripathi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center (University of Pittsburgh Cancer Institute (UPCI))</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annalisa Brenneman</last_name>
      <phone>412-623-2293</phone>
      <email>brennemana2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Leonard Appleman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center (VUMC)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VICC Recruitment and Eligibility Office</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Brian Rini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Rowell</last_name>
      <phone>214-648-7001</phone>
      <email>Amy.Rowell@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Hans Hammers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacey McQuinn</last_name>
      <phone>713-792-5578</phone>
      <email>lmcquinn@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Yanyan Tian, PhD</last_name>
      <phone>713-792-7274</phone>
      <email>ytian@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Aung Naing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Galindo</last_name>
      <phone>210-593-5202</phone>
      <email>angela.galindo@startsa.com</email>
    </contact>
    <investigator>
      <last_name>Amita Patnaik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phase I Program</last_name>
      <phone>206-606-7551</phone>
    </contact>
    <investigator>
      <last_name>Andrew Coveler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HyunJoo Ryu</last_name>
      <phone>+82-2-6072-5175</phone>
      <email>rhjstar@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Tae-Yong Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SoYoung Hwang</last_name>
      <phone>82-2-2228-8048</phone>
      <email>SYHWANG@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Sun Young Rha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SeoJin Moon</last_name>
      <phone>82-2-3010-8351</phone>
      <email>jinn@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Yoon-Koo Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Singapore (NCCS)</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Carlota Figueroa Macapagal</last_name>
      <email>Maria.C.F.M@nccs.com.sg</email>
    </contact>
    <investigator>
      <last_name>Han Chong Toh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 30, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic solid tumors</keyword>
  <keyword>advanced solid tumors</keyword>
  <keyword>Phase 1</keyword>
  <keyword>SRF388</keyword>
  <keyword>IL-27</keyword>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>cancer</keyword>
  <keyword>immuno-oncology</keyword>
  <keyword>kidney cancer</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>liver cancer</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

